个人简介

      鲁军，博士、教授、硕士生导师、毕业于香港浸会大学转化医学专业，任职于成都中医药大学药学院，研究领域主要靶向抗肿瘤功能性大分子-活性天然药物偶合物、天然产物的结构修饰以及不对称催化的手性药物研究。

      主要研究内容包括：设计、制备以及生物评价靶向抗肿瘤生物大分子-天然药物偶合物（生物大分子包括核酸、多肽、抗体等）；活性天然产物的功能性修饰以及结构改造；NHC的不对称催化以及手性药物活性评价。

      已经在Nature Communications, Journal of Enzyme Inhibition and Medicinal Chemistry，International Journal of Molecular Sciences，Research on Chemical Intermediates等国际期刊发表研究论文20余篇,申请国际专利1项，美国专利1项，中国专利5项，获批中国专利3项。主持或参与国家自然基金和地区基金9项。

代表性成果

1.Zhang H , Lu J. (co-first author) , Liu J , et al. Advances in the discovery of exosome inhibitors in cancer. J. Enzyme. Inhib. Med. Chem., 2020, 35, 1322-1330.

2.Liang C., Peng S., Li J., Lu J. (co-first author), Zhu H., Wang Y., Zhang B., Lu A., Zhang G., Inhibition of osteoblastic Smurf1 promotes bone formation in mouse models of distinctive age-related osteoporosis. Nat. Commun. 2018, 9, 3428.

3.Lu J., Wang M., Wang Z., Fu Z., Lu A., Zhang G., Advances in the discovery of cathepsin K inhibitiors on bone resorption. J. Enzyme. Inhib. Med. Chem., 2018, 33, 890-904.

4.Li F., Lu J. (co-first author), Liu J., Liang C., Wang M., Wang L., Li D., Zhang B., Lu A., Zhang G., A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nat. Commun., 2017, 8, 1390.

5.Lu J, Jiang F, Lu A, Zhang G., Linkers having a crucial role in antibody–drug conjugates[J]. Int. J. Mol. Sci., 2016, 17, 561.

6.Lu J., Fu X., Zhang G., Wang C., β-Cyclodextrin as an efficient catalyst for the one-pot synthesis of tetrahydrobenzo [b] pyran derivatives in water[J]. Res. Chem. Intermediate., 2016, 42, 417-424.